Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including tropical infectious diseases.
Partnering tabs - Core Therapeutic Areas " >Partnering tabs - Core Therapeutic Areas
Novartis is uniquely diversified across therapy areas with exposure to cutting-edge technology platforms. We have arguably the richest and broadest pipeline in the industry with more than 65 New Molecular Entities in development. Please select your therapy area of interest to connect to one of our specialist partnering professionals.
Looking for truly differentiating first or best-in-class treatments in:
- Neurodegeneration and Neuroinflammation
- Pediatric Neurological Diseases
- Psychiatry
Chi-Chi Zhu
Looking for truly differentiating first or best-in-class treatments in:
- Around Radioligand Therapies (RLT), including novel targets and advanced programs complementary to current pipeline and disease focus, isotopes and chelators for tumor specific RLT delivery
- Targeted Therapies. Novel targets complementary to pipeline / portfolio, addressing unmet needs in breast, lung, prostate, CRC, and pancreatic malignancies
- Immuno-oncology. Novel mechanisms complementary to anti-PD-1 or addressing unmet needs in breast, lung, CRC, prostate, and pancreatic malignancies
Reza Mazhari
Looking for truly differentiating first or best-in-class treatments:
- Targeted Therapies as well as
- Immuno-oncology based approaches with novel mechanisms that are complementary to our internal portfolio and pipeline addressing unmet needs in heme malignancies
- Celle & Gene. Novel T cell-based cell therapies to expand CART portfolio including solid tumors and leverage internal T-ChargeTM platform in deal-making. Advance from ex vivo HSC and CART therapy to in vivo gene therapy
Markus Werner
Other Areas - Partnering tab " >Other Areas - Partnering tab
Seeking transformative approaches to address genetic disease
Elizabeth Leshen
Ophthalmology
Seeking to develop and deliver life-changing medicines for diseases and conditions from front to back of the eye, enabled by data, transformative technologies, and partnerships.
Chris Adams
Renal
Interested in disease modifying treatments and renal indications with high unmet need.
Andreas Sailer
Respiratory
We are looking for partners to expand our portfolio with innovative and potentially transformative agents with a primary focus in subspeciality respiratory (e.g. IPF, sarcoidosis, bronchiectasis), life threatening hospital conditions (e.g. ARDS, BPD).
Andreas Sailer
We accept that innovation happens outside of areas of interest- we are still prepared to discuss transformational areas we may have missed. We have a special team for you to talk with.
Andreas Sailer
Platform Collaborations - Partnering tab " >Platform Collaborations - Partnering tab
Chemical Biology and Therapeutics (CBT).
At CBT, we strive to innovate the science of therapeutics through a dynamic culture of enabling partnerships. Through a variety of technologies and talents, we translate exceptional science into medical innovation.
Cynthia Hong
